Revolution Medicines (NASDAQ:RVMD) Stock Rating Upgraded by Wall Street Zen

Revolution Medicines (NASDAQ:RVMD) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

A number of other research analysts have also recently commented on RVMD. Brookline Capital Markets initiated coverage on Revolution Medicines in a research note on Monday, September 28th. They set a “buy” rating and a $318.00 price target on the stock. Sanford C. Bernstein raised their price target on Revolution Medicines from $151.00 to $179.00 and gave the stock a “market perform” rating in a research report on Friday, August 21st. Evercore reaffirmed an “outperform” rating and issued a $320.00 price objective on shares of Revolution Medicines in a research note on Thursday, August 27th. Piper Sandler boosted their price objective on Revolution Medicines from $210.00 to $222.00 and gave the company an “overweight” rating in a report on Thursday. Finally, The Goldman Sachs Group began coverage on Revolution Medicines in a research note on Thursday, September 24th. They set a “buy” rating and a $267.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Revolution Medicines presently has a consensus rating of “Moderate Buy” and an average target price of $263.15.

Revolution Medicines Stock Performance

Shares of RVMD stock opened at $192.28 on Friday. The firm’s 50 day moving average price is $196.88 and its 200-day moving average price is $157.56. The company has a debt-to-equity ratio of 0.44, a quick ratio of 8.34 and a current ratio of 8.36. Revolution Medicines has a one year low of $58.91 and a one year high of $224.31. The firm has a market cap of $41.59 billion, a P/E ratio of -21.11 and a beta of 1.44.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($1.90) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.35) by $0.45. The company had revenue of $197.56 million for the quarter, compared to analysts’ expectations of $25.58 million. During the same period in the previous year, the business posted ($1.61) EPS. As a group, equities research analysts predict that Revolution Medicines will post -7.88 EPS for the current year.

Insider Activity

In other Revolution Medicines news, COO Margaret A. Horn sold 4,967 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $199.24, for a total value of $989,625.08. Following the completion of the transaction, the chief operating officer owned 149,680 shares of the company’s stock, valued at $29,822,243.20. This trade represents a 3.21% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Alan B. Sandler sold 6,309 shares of the firm’s stock in a transaction that occurred on Tuesday, September 29th. The shares were sold at an average price of $202.14, for a total transaction of $1,275,301.26. Following the completion of the transaction, the insider directly owned 52,559 shares of the company’s stock, valued at $10,624,276.26. This represents a 10.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 290,991 shares of company stock worth $59,422,765 over the last 90 days. Company insiders own 7.60% of the company’s stock.

Institutional Trading of Revolution Medicines

A number of large investors have recently modified their holdings of RVMD. Alphabet Inc. acquired a new stake in shares of Revolution Medicines in the 2nd quarter valued at about $551,843,000. Assenagon Asset Management S.A. grew its stake in Revolution Medicines by 987.9% in the third quarter. Assenagon Asset Management S.A. now owns 2,181,185 shares of the company’s stock worth $447,710,000 after purchasing an additional 1,980,699 shares in the last quarter. Bank of America Corp DE acquired a new position in Revolution Medicines in the second quarter worth about $184,267,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Revolution Medicines by 82.3% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 912,335 shares of the company’s stock valued at $170,862,000 after buying an additional 411,740 shares during the last quarter. Finally, Deutsche Bank AG bought a new stake in Revolution Medicines in the second quarter valued at about $166,308,000. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Key Stories Impacting Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Strong early Rasonque sales: Revolution Medicines reported $197.6 million in third-quarter revenue, beating estimates, with Rasonque generating that amount in just five weeks after its U.S. launch. The company said more than 5,000 patients had been treated. The quarterly loss per share also came in narrower than analysts expected. Zacks article on Q3 results and Rasonque uptake
• Positive Sentiment: Analyst targets moved higher: HC Wainwright raised its target to $350 and maintained a Buy rating. RBC lifted its target to $321 with an Outperform rating; Guggenheim, Truist and TD Cowen also raised targets and retained positive ratings. These revisions signal optimism about the drug’s commercial potential and pipeline. HC Wainwright recommendations RBC target increase
• Neutral Sentiment: Long-term opportunity, but expectations are high: Rasonque’s clinical results and potential expansion into other solid tumors support the pipeline outlook. However, commentary noted that RVMD’s roughly $40 billion valuation already reflects substantial expectations, making sustained launch growth and upcoming clinical results important. Seeking Alpha analysis of Q3 results
• Negative Sentiment: Some long-range forecasts were cut: Brookline Capital Markets lowered its FY2029 EPS estimate to $8.49 from $8.94 and its FY2030 estimate to $17.41 from $18.15, though it kept a Buy rating and a $318 target.

About Revolution Medicines

Revolution Medicines, Inc is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company’s research centers on RAS proteins, which can contribute to the growth of many cancers.

The company’s pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.